Hyperphosphatemia

First-in-Class Treatment Shows Promise in Hyperphosphatemia Trial

By February 15, 2017

The trial demonstrated a statistically significant difference in serum phosphorus levels for the tenapanor group over the placebo group.

Auryxia Supply May Be Limited Due to Production Issue

By August 01, 2016

Keryx Biopharmaceuticals announced an interruption will occur in the supply of Auryxia (ferric citrate) tablets due to a production-related issue.

Cocoa Flavanol May Be Beneficial for ESRD Patients

December 21, 2015

For patients with end-stage renal disease (ESRD), daily cocoa flavanol (CF) ingestion alleviates acute and chronic hemodialysis (HD)-induced vascular dysfunction, according to a study published online in the Clinical Journal of the American Society of Nephrology.

New Oral Tx for Hyperphosphatemia in CKD Launched

By December 22, 2014

Keryx announced the launch of Auryxia (ferric citrate) tablets to control serum phosphorous levels in patients with chronic kidney disease (CKD) on dialysis.

Ferric Citrate OK'd for Hyperphosphatemia in CKD Patients

September 05, 2014

Keryx Biopharmaceuticals announced that the Food and Drug Administration (FDA) has approved Ferric Citrate (formerly known as Zerenex) for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Keryx Submits NDA for Hyperphosphatemia Drug, Zerenex

August 08, 2013

A New Drug Application (NDA) was submitted to the FDA for Zerenex (ferric citrate coordination complex) for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis.